

August 01, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that Optival Health Solutions Private Limited, the Subsidiary Company has received one suspension order of Drug License for Two days a store situated at Telangana. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details is given below:

Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/contravention(s) committed or alleged to be committed	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director, Drugs Control Administration, Patancheru, Telangana	Suspension of Drug License for two days of a store situated at BHEL LIG, Patancheru, Telangana.	Order received on 31.07.2024	Violation of Rules 65(2), 65(4)(3)(ii) under Drugs and Cosmetics Act, 1940 and Rules 1945	Potential Revenue Loss of Rs~1.46 Lacs.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460